BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Orca Bio’s Blood Cancer Therapy Orca-T Has Strong Showing at ASH

  Orca-T demonstrated significantly higher graft-versus-host disease-free, relapse-free survival (GRFS) rates compared to patients who received standard of care.

  December 13, 2021

   · 

  2 min read

   · 

  Sreetama Dutt
• 

  Business

  Eli Lilly and Foghorn to Leverage Gene Traffic Control in Oncology

  The collaboration covers the co-development and co-commercialization of products created from Foghorn’s BRM oncology program and another oncology target.

  December 13, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Novartis’ Jeff Legos Discusses Progress and Potential in Oncology

  Making its ASH debut this year was Novartis’ T-Charge CAR-T platform. Novartis presented early data from two first-in-human dose-escalation trials: YTB323 and PHE885.

  December 13, 2021

   · 

  6 min read

   · 

  Heather McKenzie
• 

  Deals

  CSL and Vifor Confirm Advanced Talks of Potential $8 Billion+ Acquisition

  The deal, which could be worth as much as $12 billion USD, was also confirmed by CSL speaking to Reuters Monday morning.

  December 13, 2021

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Career Advice

  How to Improve Your Follow Up After Interview

  Following up after an interview can be essential to help you gain peace of mind and reinforce your interest. Here’s how to improve follow up after interview.

  December 13, 2021

   · 

  3 min read

   · 

  Porschia Parker-Griffin
• 

  Drug Development

  Novartis’ Scemblix Shines at ASH While Sandoz Rumors Swirl

  Novartis is going full steam ahead with its cancer development efforts, recently posting positive results from two ongoing trials for lymphoma and leukemia.

  December 13, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Highlights from ASH: GBT, Jazz, Regeneron and More

  The following features are highlights from the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, held in-person in Atlanta, GA, and virtually from December 11 to 14.

  December 13, 2021

   · 

  4 min read

   · 

  Vanessa Doctor, RN
• 

  Deals

  Pfizer Augments Inflammation and Immunology Business with $6.7 Billion Buy

  Arena Pharmaceuticals’ share price nearly doubled in premarket trading after Pfizer announced it was acquiring the company and its diverse portfolio of developmental and clinical assets.

  December 13, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Pharm Country

  Omicron Continues to Cause Confusion about Vaccine Response and Origins

  A study out of the University of Oxford found that two shots of the Pfizer-BioNTech vaccine or the AstraZeneca-Oxford vaccine were not as effective at against Omicron as they were against previous variants.

  December 13, 2021

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  Halberd’s Laser Tech Demonstrates Potential for Treating Alzheimer’s and other CNS Diseases

  Halberd announced that preliminary testing of its extracorporeal laser irradiation methodologies completely eradicated Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF).

  December 13, 2021

   · 

  3 min read

   · 

  Mark Terry